Navigation Links
HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Date:5/29/2008

als and targeted therapies.

"We are pleased to see the use of AQUA(R) technology expanded within this preeminent cancer research center," said John L. Tonkinson, Ph.D., Vice President of Business Development at HistoRx. "We look forward to exciting new applications and results utilizing AQUA(R) technology coming out of the Dana-Farber/Harvard Cancer Center institutions."

About the HARP(TM) Program

The HistoRx Academic Research Program (HARP) provides oncologists and pathologists at leading academic research institutions in North America and Europe access to the AQUA(R) technology for use exclusively in noncommercial research. Academic and other not-for-profit research institutions are eligible to participate in HARP. Membership benefits include noncommercial use of the AQUA platform. (System components include AQUA(R) software for tissue analysis and the PM-2000(TM) image analyzer.)

About HistoRx (http://www.historx.com)

HistoRx is developing and commercializing pioneering quantitative histopathology technology that provides exceptional measurement and localization of protein biomarkers in their natural context within tissue. The HistoRx proprietary AQUA(R) technology is the first platform capable of measuring biomarker concentration with subcellular resolution to generate more precise, efficient, and cost-effective answers about the safety and effectiveness of new therapeutics in development as well as enable the development of companion diagnostic tests for targeted therapies. HistoRx services are used by pharmaceutical and biotechnology companies throughout discovery research, preclinical studies, and clinical drug development. HistoRx companion diagnostic products are linked to our partners' drug candidates in development to predict therapeutic outcome. HistoRx also pursues internal programs to develop proprietary in vitro diagnostics that offer substantial improvements over ex
'/>"/>

SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
2. Favrille Announces Workforce Reduction
3. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
4. Genmab Announces 2008 First Quarter Results
5. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
6. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. WuXi PharmaTech Announces First Quarter 2008 Results
9. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
10. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
11. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 LayerBio is an MIT ... wound care. The National Eye Institute (NEI) at the ... Phase I SBIR grant to develop a drug-eluting intraocular ... most common cause of vision loss in people over ... According to Dr. Ken Mandell, LayerBio’s Founder and CEO, ...
(Date:12/19/2014)... 19, 2014 The empty capsules ... rising ageing population and technological innovations in the ... industries are catalysing the growth of the empty ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , The ... as new entrants/smaller firms to gauge the pulse ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... March 7 On Thursday, March 13, 2008,at ... members,of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... call to discuss the company,s 2007 fourth,quarter achievements ... Numbers Thursday, March 13 8:30 a.m. ...
... team of researchers from the departments of macromolecular science ... of Engineering and the Louis Stokes Cleveland Department of ... a new type of polymer that displays chemoresponsive mechanic ... to soft plastic and vice versa in seconds when ...
... March 6 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... to the,Company,s Board of Directors., "As the ... of the former Bayer Diagnostics and Diagnostic Products,Corporation, ... our Board," said Dr.,Paul Walker, President and CEO ...
Cached Biology Technology:Researchers engineer new polymers to change their stiffness and strength when exposed to liquids 2Researchers engineer new polymers to change their stiffness and strength when exposed to liquids 3Spectral appoints Anthony Bihl to Board of Directors 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... (GIVI) have identified a previously unknown function of APOBEC3G (A3G), ... lead to new approaches for controlling HIV infection. , ... of the National Academy of Sciences, USA. , The research, ... C. Greene, MD, PhD, explains why CD4 T cells ?the ...
... or stroke, paramedics, doctors, and nurses follow standardized protocols for ... odds for a full recovery. That's not the case if ... be fatal within a few hours and is often not ... new, multicenter research consortium, called Protocolized Care for Early Septic ...
... individual's immune system controls HIV during the earliest phases ... versions of key immune-system molecules called HLA Class I ... fragments of viral protein those molecules display to the ... a report in the November issue of PLOS Medicine, ...
Cached Biology News:Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2New study aims to stop sepsis in its tracks 2New study aims to stop sepsis in its tracks 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
... of monoclonal antibody reactive against the complex IV ... highest in growing cultured cells. SURF1 is an ... is thought to participate in the folding of ... subunit. Mutations of SURF1, particularly ones that result ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: